Phase 3 Recruiting NIH
This phase III trial compares the effect of adding cemiplimab to standard therapy (surgery with or without radiation) versus standard therapy alone in treating patients with stage III/IV squamous cell skin cancer that is able to be removed…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06568172
Sites in Nebraska: - Nebraska Medicine-Bellevue — Bellevue, Nebraska
- Nebraska Cancer Specialists/Oncology Hematology West PC - MECC — Omaha, Nebraska
- Nebraska Methodist Hospital — Omaha, Nebraska
- Nebraska Medicine-Village Pointe — Omaha, Nebraska
- University of Nebraska Medical Center — Omaha, Nebraska
Phase 3 Recruiting Academic/Other
This phase III trial tests if gabapentin can prevent the need for opiate pain medication for mouth sores (oral mucositis) in patients undergoing treatment with chemotherapy and radiation for squamous cell carcinoma of the head and neck reg…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06992427
Sites in Nebraska: - Nebraska Medicine-Bellevue — Bellevue, Nebraska
- CHI Health Good Samaritan — Kearney, Nebraska
- Nebraska Methodist Hospital — Omaha, Nebraska
- Nebraska Medicine-Village Pointe — Omaha, Nebraska
- University of Nebraska Medical Center — Omaha, Nebraska
Phase 3 Recruiting Industry
The goal of this study is to assess the safety and effectiveness of Dostarlimab compared to Placebo in adult participants with Head and Neck Squamous Cell Carcinoma (HNSCC)
Sponsor: GlaxoSmithKline
NCT ID: NCT06256588
Sites in Nebraska: - GSK Investigational Site — Omaha, Nebraska
Phase 2 Recruiting Network
This phase II trial studies how well radiation therapy with or without cisplatin works in treating patients with stage III-IVA squamous cell carcinoma of the head and neck who have undergone surgery. Radiation therapy uses high energy x-ra…
Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT02734537
Sites in Nebraska: - Nebraska Cancer Specialists/Oncology Hematology West PC — Grand Island, Nebraska
- Heartland Hematology and Oncology — Kearney, Nebraska
- CHI Health Good Samaritan — Kearney, Nebraska
- Nebraska Hematology and Oncology — Lincoln, Nebraska
- Nebraska Cancer Research Center — Lincoln, Nebraska
Phase 2 Recruiting NIH
This phase II trial tests how well nivolumab and ipilimumab immunotherapy with or without cabozantinib works in treating patients with nasopharyngeal cancer that has come back (after a period of improvement) (recurrent), has spread from wh…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05904080
Sites in Nebraska: - Nebraska Cancer Specialists/Oncology Hematology West PC - MECC — Omaha, Nebraska
- Nebraska Methodist Hospital — Omaha, Nebraska
- Oncology Associates PC — Omaha, Nebraska
Phase 2 Recruiting NIH
This phase II trial tests effects of nivolumab in combination with chemotherapy drugs prior to radiation therapy patients with nasopharyngeal carcinoma (NPC). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06064097
Sites in Nebraska: - Children's Hospital and Medical Center of Omaha — Omaha, Nebraska
- University of Nebraska Medical Center — Omaha, Nebraska
Phase 2 Recruiting Industry
A Phase II, Multicenter, Open-Label Trial of DB-1311 in combination with BNT327 or DB-1305 in Participants with Advanced/Metastatic Solid Tumors
Sponsor: DualityBio Inc.
NCT ID: NCT06953089
Sites in Nebraska: - USA14-0 — Lincoln, Nebraska
Phase 1, Phase 2 Recruiting Industry
This is a Phase 1/2, open-label, multicenter study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of TER-2013 in patients with advanced solid tumors harboring AKT/PI3K/PTEN pathway alteratio…
Sponsor: Terremoto Biosciences Inc.
NCT ID: NCT07109726
Sites in Nebraska: - Nebraska Cancer Specialists — Omaha, Nebraska
Phase 1, Phase 2 Recruiting Industry
The goal of this clinical trial is to learn if an investigational drug CP-383 works to treat advanced cancer. It will also learn about the safety of CP-383. The main questions if aims to answer are: * Does CP-383 slow or stop the growth of…
Sponsor: Tasca Therapeutics
NCT ID: NCT07030257
Sites in Nebraska: - Nebraska Cancer Specialists — Omaha, Nebraska
Phase 1, Phase 2 Recruiting Industry
A Phase 1/2a Dose Escalation and Expansion Study of the Safety, Tolerability, and Preliminary Clinical Activity of 177LuBetaBart, a 177Lu-Labeled Anti-B7-H3 Monoclonal Antibody, in Patients with Relapsed/Refractory, Locally Advanced Inoper…
Sponsor: Radiopharm Theranostics, Ltd
NCT ID: NCT07189871
Sites in Nebraska: - Nebraska Cancer Specialists — Omaha, Nebraska
- XCancer — Omaha, Nebraska
Phase 1 Recruiting Industry
This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect of biomarkers of zanzalintinib administered alon…
Sponsor: Exelixis
NCT ID: NCT05176483
Sites in Nebraska: - Exelixis Clinical Site #2 — Omaha, Nebraska
- Exelixis Clinical Site #5 — Omaha, Nebraska
Phase 1 Recruiting Industry
TTX-080-001 is a Phase 1, open label, dose escalation and dose expansion clinical study to determine the safety, tolerability, and recommended Phase 2 dose of TTX-080 monotherapy (HLA-G inhibitor) and in combination with either pembrolizum…
Sponsor: Tizona Therapeutics, Inc
NCT ID: NCT04485013
Sites in Nebraska: - Nebraska Cancer Center Oncology Hematology West P.C. — Omaha, Nebraska
Phase 1 Recruiting Industry
This is a first-in-human, Phase 1, non-randomized, multicenter, open-label clinical study designed to investigate the safety, tolerability, dosimetry, biodistribution, and pharmacokinetics (PK) of \[225Ac\]-FPI-2068, \[111In\]-FPI-2107, an…
Sponsor: AstraZeneca
NCT ID: NCT06147037
Sites in Nebraska: - Research Site — Omaha, Nebraska
Recruiting Academic/Other
This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in Nebraska: - CHI Health Saint Francis — Grand Island, Nebraska
- Nebraska Cancer Specialists/Oncology Hematology West PC — Grand Island, Nebraska
- CHI Health Good Samaritan — Kearney, Nebraska
- Saint Elizabeth Regional Medical Center — Lincoln, Nebraska
- Alegent Health Immanuel Medical Center — Omaha, Nebraska
NA Recruiting Industry
This study intends to explore feasibility, acceptability, and outcomes related to the use of a digital health coaching intervention for individuals who have completed primary therapy for cancer. Up to 625 individuals with diverse cancer di…
Sponsor: Pack Health
NCT ID: NCT05349227
Sites in Nebraska: - University of Nebraska Medical Center — Omaha, Nebraska